一项新的研究发现，与当前血压药物能防止大肠癌相反，服用β-受体阻滞剂治疗高血压并不减少一个人发展罹患大肠癌的风险。相关研究论文发表在Cancer杂志上，该研究还表明即使长期使用β受体阻滞剂的亚型并无明显减少大肠癌的危险。
近年来，研究者们认为β受体阻滞剂的服用可能与癌症的风险降低有关。这个理论源于动物实验研究和实验室研究中发现应激激素去甲肾上腺素能促进癌细胞的生长和扩散。β受体阻滞剂抑制去甲肾上腺素，所以认为它能具有抗癌特性。
β-受体阻滞剂对大肠癌风险的影响在先前的一些研究中实际上得出了不一致的结果。为了更深入解决这一问题，德国癌症研究中心的Michael Hoffmeister博士和他的同事们对2003年至2007年与1762例大肠癌和1708未患癌症的人进行了随访研究。
考虑某些病人特征（如体重和吸烟状况）和其他可能影响结果的因素后，研究人员并没有发现使用β受体阻滞剂和大肠癌风险降低之间的联系。总的来说，这项研究结果并不支持降血压药物防止大肠癌这一假设。（生物谷：Bioon.com）
doi:10.1002/cncr.26727
PMC:
PMID:
Beta blocker use and colorectal cancer risk?
Lina Jansen MSc, Janina Below, Jenny Chang-Claude PhD, Hermann Brenner MD, MPH, Michael Hoffmeister PhD
Abstract
BACKGROUND:
Recently, it has been postulated that long-term use of beta blockers might decrease the risk of certain types of cancer because of weakening of norepinephrine signaling. Previous studies on colorectal cancer (CRC) yielded inconsistent results, but lacked information on covariates. Thus, the authors investigated the association of beta blocker use and CRC risk in a large population-based case-control study (DACHS study).
METHODS:
Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany. The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression. In addition, site- and stage-specific analyses were performed.
RESULTS:
After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use. Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations. In stage-specific analyses, long-term beta blocker use (6+ years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27).
CONCLUSIONS:
Our adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of CRC. In contrast, we found a positive association of long-term beta blocker use and risk of stage IV CRC. The latter result should be further evaluated in future studies.
